Schizophrenia is a severe mental illness that represents a significant public health burden. No treatments are FDA approved for negative symptoms of schizophrenia, primarily because there is no valid, reliable measure for negative symptoms. A new negative symptom measure, the Negative Symptom Rating Scale (NSRS), is in the initial phases of validation. The current study assesses the convergent validity of the scale by examining the relationship between the NSRS and expressed facial affect. The study also sought to clarify the relationship between expressed facial affect and functioning. The results revealed a significant relationship between expressed facial affect and the NSRS subscale of blunted affect, as predicted. However, there was not a significant relationship between expressed facial affect and functioning. These results provide initial evidence for the convergent validity of the scale. Currently, there is an ongoing research study to further assess the reliability and validity of the NSRS.